Zafgen Company Profile (NASDAQ:ZFGN)

Analyst Ratings

Consensus Ratings for Zafgen (NASDAQ:ZFGN) (?)
Ratings Breakdown: 6 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $10.17 (234.43% upside)

Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016FBR & CoDowngradeOutperform -> Market Perform$20.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/5/2016Royal Bank Of CanadaReiterated RatingOutperform$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2016SunTrust Banks Inc.Reiterated RatingHold$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Zafgen (NASDAQ:ZFGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zafgen (NASDAQ:ZFGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.75)($0.75)($0.75)
Q2 20162($0.66)($0.62)($0.64)
Q3 20162($0.76)($0.68)($0.72)
Q4 20162($0.89)($0.69)($0.79)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zafgen (NASDAQ:ZFGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zafgen (NASDAQ:ZFGN)
DateHeadline
07/29/16 07:43 PMAnalysts: Zafgen, Inc. (NASDAQ:ZFGN) stock is worth $4.5 ... - Review Fortune
07/29/16 08:53 AMZafgen (ZFGN) Is in Oversold Territory: What's Next? -
07/28/16 07:56 PMHot Biotech Stocks Recap: Zafgen, Inc. (NASDAQ:ZFGN), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - The Voice Registrar
07/25/16 07:38 PMHC Stocks Overview: Celgene Corporation (NASDAQ:CELG) Zafgen Inc (NASDAQ:ZFGN) - share market updates (press release)
07/25/16 07:38 PMCurrent Zafgen, Inc. (NASDAQ:ZFGN) PT Means Stock Is Worth Almost $6 - Review Fortune
07/25/16 04:16 AMZafgen (ZFGN) Shares are Down -55.84% - Trade Calls
07/25/16 04:16 AMNoteworthy Analysts Suggestions: Zafgen, Inc. (NASDAQ:ZFGN) , St. Jude Medical, Inc. (NYSE:STJ) - Street Updates
07/23/16 08:40 AMShares Stumbling of Late: Zafgen, Inc. (NASDAQ:ZFGN) - TGP
07/22/16 07:13 PMOption Market: Zafgen Inc (NASDAQ:ZFGN) Risk Hits An Extreme High - CML News
07/22/16 07:13 PMZafgen, Inc. (NASDAQ:ZFGN) Insiders Look Optimistic About Prospects - Review Fortune
07/22/16 07:13 PMZafgen Inc. (ZFGN) is Trading Lower on Unusual Volume for July 21 - Equities.com
07/22/16 10:22 AMBiotech Stocks To Put On Your Watch List: Zafgen, Inc. (NASDAQ:ZFGN), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar
07/22/16 10:22 AMWorthy Stock Update: Zafgen (ZFGN) - News Oracle
07/22/16 10:22 AMNoteworthy Analysts Suggestions: Zafgen, Inc. (NASDAQ:ZFGN) , Evoke Pharma, Inc. (NASDAQ:EVOK) - Street Updates
07/22/16 10:22 AMZafgen Inc. (ZFGN) is Trading Lower on Unusual Volume for July 20 - Equities.com
07/22/16 10:22 AMCanaccord Weighs in on Zafgen Inc (ZFGN) in Wake of Suspended Development for Weight Loss Drug Beloranib - Smarter Analyst
07/21/16 10:16 AMZafgen Inc. (ZFGN) Sank To A New Low After Development Of Beloranib Suspended
07/21/16 08:30 AMThe Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen -
07/20/16 08:34 PMStock Bending Down in Today's Session: Zafgen, Inc. (NASDAQ:ZFGN) - TGP
07/20/16 08:34 PMFBR Capital Cuts Rating On Zafgen, Inc. (ZFGN) - Finance Daily
07/20/16 08:34 PMZafgen, Inc. (ZFGN) Hits 52-Week Low - Finance Daily
07/20/16 08:34 PMHome Biotech Stocks Zafgen, Inc. | $ZFGN Stock | Shares Crash Down On Announcement Of... - TickerTV News (press release)
07/20/16 10:19 AMZafgen Suspends Development Of Beloranib; Shares Plunge More Than 40%
07/20/16 10:19 AMZafgen Inc. (ZFGN) Is Falling After Development Of Beloranib Suspended
07/20/16 10:19 AMZafgen (ZFGN) to Suspend Beloranib Development; Will Refocus on MetAP2 Inhibitor ZGN-1061
07/20/16 10:19 AMFBR Capital Cuts Rating On Zafgen, Inc. (ZFGN)
07/20/16 10:19 AMZafgen Shares Crash Down On Announcement Of Cutting Workforce
07/20/16 09:45 AMWhy Zafgen (ZFGN) Stock Is Tanking Today -
07/20/16 08:44 AMZafgen Halts Development of Beloranib, to Cut Jobs by ~34% -
07/20/16 08:23 AMZafgen downgraded by FBR Capital -
07/19/16 07:38 PMZafgen, Inc. (NASDAQ:ZFGN): Stock Insight and Session Performance Spotcheck - Press Telegraph
07/19/16 07:38 PMConsensus Analyst Target Price Check for Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
07/19/16 07:38 PMZafgen (ZFGN) to Suspend Beloranib Development; Will Refocus on MetAP2 Inhibitor ZGN-1061 - StreetInsider.com
07/19/16 04:35 PMZafgen shares drop more than 40% as drug focus shifted -
07/19/16 04:22 PMZAFGEN, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex -
07/19/16 03:47 PMZafgen to scrap obesity drug, cut jobs -
07/19/16 03:07 PM4:07 pm Zafgen suspends development of Beloranib; co believes that its current cash balance is sufficient to fund operations through the end of 2018 -
07/19/16 03:05 PMZafgen Refocuses Resources on Development of Differentiated Second-Generation MetAP2 Inhibitor ZGN-1061 - [GlobeNewswire] - -ZGN-1061 in Phase I Development for Severe and Complicated Obesity Indications-. -Suspending Development of Beloranib; Implementing Strategic Restructuring to Align Operations with Clinical Development ...
07/19/16 08:22 AMZafgen, Inc. (NASDAQ:ZFGN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/17/16 04:28 AMWere Analysts Bullish Zafgen Inc (NASDAQ:ZFGN) This Week? - Consumer Eagle
07/16/16 06:40 PMZafgen, Inc. (NASDAQ:ZFGN) Stock Rating View - Engelwood Daily
07/16/16 06:40 PMZafgen Inc Realized Volatility Hits a Dropping Level - CML News
07/16/16 06:40 PMFocusing on Shares of: Zafgen, Inc. (NASDAQ:ZFGN) - TGP
07/16/16 06:40 PMStock Performance Check on : Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
07/15/16 12:47 PMZafgen, Inc. (NASDAQ:ZFGN) Updated Price Targets - FTSE News
07/15/16 12:47 PMCrowd Rating and Earnings Recap for Zafgen, Inc. (NASDAQ:ZFGN) - Telanagana Press
07/15/16 12:47 PMCurrent Sentiment and Impact Score Watch:Zafgen, Inc. (NASDAQ:ZFGN):Zafgen, Inc. (NASDAQ:ZFGN) - Press Telegraph
07/14/16 07:41 PMAnalysts Have a Consensus Buy on Shares of: Zafgen, Inc. (NASDAQ:ZFGN) - Telanagana Press
07/14/16 07:41 PMEquity Insight on Zafgen, Inc. (NASDAQ:ZFGN) Shares - Telanagana Press
07/14/16 07:41 PMZafgen, Inc. (NASDAQ:ZFGN): Stock Review and Performance Update - Press Telegraph

Social

About Zafgen

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZFGN
  • CUSIP:
Key Metrics:
  • Previous Close: $3.04
  • 50 Day Moving Average: $5.63
  • 200 Day Moving Average: $6.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $82.91M
  • Beta: -1.14
  • Current Year EPS Consensus Estimate: $-2.62 EPS
  • Next Year EPS Consensus Estimate: $-2.29 EPS
Additional Links:
Zafgen (NASDAQ:ZFGN) Chart for Saturday, July, 30, 2016